KEY FINDINGS
The global peripheral artery disease market is projected to grow at a CAGR of 10.35% during the forecast period, 2021-2028. The market growth is propelled by technological advancements in treatment, increasing geriatric population, healthcare infrastructure, and improving reimbursement and insurance policies in developing economies.
MARKET INSIGHTS
Peripheral artery disease (PAD) is a disease of blood vessels located outside the heart and brain. It occurs due to plaque build-up in arteries that carry blood to limbs, organs, and head. One of the primary drivers of market growth is enhanced insurance and reimbursement policies. Governments across the world are striving to provide quality healthcare for their population.
Moreover, health issue awareness, health insurance promotion, and ensuring strong infrastructure are among the authorities' activities for people's welfare. In 2017, the National Health Service Surveys reported a growth in total health expenditure from 2009. It expanded its three primary social health insurance schemes to cover more than 95% of the population. Such factors promote market growth. However, the high competition and strict approval process hamper the market growth.
REGIONAL INSIGHTS
The global peripheral artery disease market growth analysis includes the assessment of North America, Europe, Asia-Pacific, and Rest of World. Asia-Pacific is evaluated to fare the highest in terms of CAGR by 2028. There is a growing demand for advanced peripheral disease devices in the region due to the rising aging population.
COMPETITIVE INSIGHTS
There is high competition among well-established players of the market increasing mergers & acquisitions to expand their product portfolio. Some of the key players in the market include Biotronik Inc, Bayer AG, Abbott Laboratories, Angiodynamics Inc, B Braun Melsungen AG, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. ENHANCED REIMBURSEMENT AND INSURANCE POLICIES
3.1.2. TECHNOLOGICAL INNOVATIONS IN TREATMENT OPTIONS
3.1.3. RISING AGING POPULATION
3.1.4. HEALTHCARE INFRASTRUCTURE IN DIFFERENT ECONOMIES
3.2. KEY RESTRAINTS
3.2.1. STRINGENT APPROVAL PROCESS
3.2.2. OCCURRENCE OF CLINICAL FAILURE AFTER SUCCESSFUL INTERVENTIONS
3.2.3. HIGH COMPETITION AMONG THE MARKET PLAYERS
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON PERIPHERAL ARTERY DISEASE MARKET
4.2. KEY INVESTMENT INSIGHTS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
5. MARKET BY DEVICES
5.1. PERIPHERAL STENTS
5.1.1. SELF-EXPANDABLE
5.1.2. BALLOON-EXPANDABLE
5.1.3. COVERED
5.1.4. DRUG-ELUTING STENTS
5.2. PERIPHERAL ANGIOPLASTY BALLOONS
5.2.1. OLD/NORMAL BALLOONS
5.2.2. CUTTING & SCORING BALLOONS
5.2.3. DRUG-COATED BALLOONS
5.3. PLAQUE MODIFICATION DEVICES
5.3.1. THROMBECTOMY DEVICES
5.3.1.1. MECHANICAL
5.3.1.2. ASPIRATION
5.3.1.3. RHEOLYTIC
5.3.2. ATHERECTOMY DEVICES
5.4. INFERIOR VENA CAVA (IVC) FILTERS
5.4.1. PERMANENT FILTERS
5.4.2. RETRIEVABLE FILTERS
5.5. HEMODYNAMIC FLOW ALTERATION DEVICES
5.5.1. EMBOLIC PROTECTION DEVICES
5.5.2. CHRONIC TOTAL OCCLUSION DEVICES
5.6. PERIPHERAL CATHETERS
5.6.1. ANGIOGRAPHY CATHETERS
5.6.2. GUIDING CATHETERS
5.7. PERIPHERAL ACCESSORIES
5.7.1. PERIPHERAL VASCULAR CLOSURE DEVICES
5.7.2. GUIDEWIRES
5.7.3. BALLOON INFLATION DEVICES
5.7.4. INTRODUCER SHEATHS
6. GEOGRAPHICAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. MARKET SIZE & ESTIMATES
6.1.2. KEY GROWTH ENABLERS
6.1.3. KEY CHALLENGES
6.1.4. KEY PLAYERS
6.1.5. COUNTRY ANALYSIS
6.1.5.1. UNITED STATES
6.1.5.2. CANADA
6.2. EUROPE
6.2.1. MARKET SIZE & ESTIMATES
6.2.2. KEY GROWTH ENABLERS
6.2.3. KEY CHALLENGES
6.2.4. KEY PLAYERS
6.2.5. COUNTRY ANALYSIS
6.2.5.1. GERMANY
6.2.5.2. FRANCE
6.2.5.3. UNITED KINGDOM
6.2.5.4. ITALY
6.2.5.5. RUSSIA
6.2.5.6. BELGIUM
6.2.5.7. POLAND
6.2.5.8. REST OF EUROPE
6.3. ASIA-PACIFIC
6.3.1. MARKET SIZE & ESTIMATES
6.3.2. KEY GROWTH ENABLERS
6.3.3. KEY CHALLENGES
6.3.4. KEY PLAYERS
6.3.5. COUNTRY ANALYSIS
6.3.5.1. CHINA
6.3.5.2. JAPAN
6.3.5.3. INDIA
6.3.5.4. AUSTRALIA & NEW ZEALAND
6.3.5.5. SOUTH KOREA
6.3.5.6. INDONESIA
6.3.5.7. THAILAND
6.3.5.8. VIETNAM
6.3.5.9. REST OF ASIA-PACIFIC
6.4. REST OF WORLD
6.4.1. MARKET SIZE & ESTIMATES
6.4.2. KEY GROWTH ENABLERS
6.4.3. KEY CHALLENGE
6.4.4. KEY PLAYERS
6.4.5. REGIONAL ANALYSIS
6.4.5.1. LATIN AMERICA
6.4.5.2. MIDDLE EAST & AFRICA
7. COMPETITIVE LANDSCAPE
7.1. KEY STRATEGIC DEVELOPMENTS
7.1.1. MERGERS & ACQUISITIONS
7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
7.1.3. PARTNERSHIPS & AGREEMENTS
7.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS & DIVESTITURES
7.2. COMPANY PROFILES
7.2.1. ABBOTT LABORATORIES
7.2.2. ANGIODYNAMICS INC
7.2.3. BAYER AG
7.2.4. B BRAUN MELSUNGEN AG
7.2.5. BIOTRONIK INC
7.2.6. BECTON, DICKINSON AND COMPANY (C R BARD)
7.2.7. BOSTON SCIENTIFIC CORPORATION
7.2.8. CARDINAL HEALTH INC
7.2.9. COOK MEDICAL INC
7.2.10. KONINKLIJKE PHILIPS NV (PHILIPS)
7.2.11. MEDTRONIC PLC
7.2.12. TELEFLEX MEDICAL
7.2.13. TERUMO CORPORATION
1. ABBOTT LABORATORIES
2. ANGIODYNAMICS INC
3. BAYER AG
4. B BRAUN MELSUNGEN AG
5. BIOTRONIK INC
6. BECTON, DICKINSON AND COMPANY (C R BARD)
7. BOSTON SCIENTIFIC CORPORATION
8. CARDINAL HEALTH INC
9. COOK MEDICAL INC
10. KONINKLIJKE PHILIPS NV (PHILIPS)
11. MEDTRONIC PLC
12. TELEFLEX MEDICAL
13. TERUMO CORPORATION
